EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects

Carina Lundby iD, Barbara Farrell iD, Amanda Wilson

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16078 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Carina Lundby und 2 weiteren Autor:innen. Beteiligte Einrichtung: Geriatric Day Hospital, Bruyère Continuing Care, Ottawa, Canada. Hauptthemen laut MEDLINE: Deprescriptions, Cholinergic Antagonists, Cognition. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anticholinergic‐induced cognitive impairment may be partially reversible upon cessation. A barrier to deprescribing of anticholinergics is the unknown risk of anticholinergic adverse drug withdrawal events (ADWE), with only limited information available on the incidence, timing and severity of anticholinergic ADWE. We report the case of a 76‐year‐old woman who experienced significant cognitive improvement following deprescribing long‐term use of a strong anticholinergic drug, doxepin, and dose reduction of another possible anticholinergic agent. The patient decided to abruptly stop taking doxepin, despite a planned careful taper with twice weekly monitoring, but did not experience any severe anticholinergic ADWE and subsequently had significantly improved cognitive function. Future research should focus on better understanding the risk of anticholinergic ADWE so that anticholinergic deprescribing decisions, including how often and by how much to taper, can be made confidently and safely.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeprescriptionsCholinergic AntagonistsCognitionHumansFemaleAgedSubstance Withdrawal SyndromeCognitive Dysfunction

Stichwörter der Autor:innen

antidepressantsdementiaelderlygeriatric medicinepharmacotherapy

Substanzen

Cholinergic Antagonists

Autor:innen und Institutionen

  • Geriatric Day Hospital, Bruyère Continuing Care, Ottawa, Canada.
  • Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense M, Denmark.
  • Hospital Pharmacy Funen, Odense University Hospital, Odense C, Denmark.
  • Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense M, Denmark.
  • Department of Family Medicine, University of Ottawa, Ottawa, Canada.
  • School of Pharmacy, University of Waterloo, Waterloo, Canada.

ORCID-Profile: Carina Lundby, Barbara Farrell

Zitieren

APA

Lundby, C., Farrell, B., & Wilson, A. (2024). Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16078

Vancouver

Lundby C, Farrell B, Wilson A. Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16078

BibTeX
@article{Lundby2024,
  author = {Lundby, Carina and Farrell, Barbara and Wilson, Amanda},
  title = {Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16078}
}
Kostenlos starten →